5 completed, 5 unknown, 4 recruiting, 2 active not recruiting. 11 Phase 2, 3 Phase 1, 2 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Estrogen Receptor Positive Tumor: new trials by email Literature Review of Estrogen Receptor Positive Tumor trials Research Report on Estrogen Receptor Positive Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas Elacestrant - Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 30 | 2026-03-25 | 2026-05-22 |
| Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients Skin tests - Breast Cancer, Estrogen Receptor Positive Tumor | Unknown | European Institute of Oncology | 150 | 2024-05-27 | 2024-06-26 | |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk Ovarian function suppression with endocrine treatments - Breast Cancer, Estrogen Receptor Positive Tumor | Phase 4 | Recruiting | Gangnam Severance Hospital | 418 | 2023-02-06 | 2025-05-22 |
| Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer Trastuzumab Pyrotinib Exemestane Dalpiciclib - Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 30 | 2022-09-01 | 2023-02-21 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Vic-trastuzumab duocarmazine (SYD985) + paclitaxel - HER2-positive Breast Cancer, HER2 Low | Phase 1 | Withdrawn | QuantumLeap Healthcare Collaborative | 2021-07-28 | 2023-11-18 | |
| The MASTER Study (MAmmary Cancer STatin ER Positive Study) Atorvastatin 80 Mg Oral Tablet, Placebo oral tablet - Breast Cancer Female, Estrogen Receptor Positive Tumor | Phase 3 | Recruiting | Aarhus University Hospital | 3360 | 2021-01-04 | 2021-01-14 |
| To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) Paclitaxel, Trastuzumab, Pertuzumab - Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 147 | 2019-04-16 | 2026-10-21 |
| Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression Tamoxifen - Neuroendocrine Tumors, Progesterone Receptor Positive Tumor | Phase 2 | Completed | AC Camargo Cancer Center | 23 | 2019-03-13 | 2024-05-06 |
| A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer Focus Group, Text Message, Best Practice - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Not applicable | Unknown | Thomas Jefferson University | 332 | 2018-11-07 | 2024-06-10 |
| Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer Surgical resection, Stereotactic body radiotherapy, Radiofrequency ablation - Breast Cancer, Recurrent Breast Cancer | Phase 2 | Unknown | Gangnam Severance Hospital | 110 | 2018-08-01 | 2019-02-15 |
| Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer Observation - Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor | Active not recruiting | North Eastern German Society of Gynaecological Oncology | 1191 | 2018-07-17 | 2026-04-13 | |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer H3B-6545 - Breast Neoplasms, Breast Cancer | Phase 1 / Phase 2 | Completed | Eisai Inc. | 151 | 2017-08-23 | 2025-02-25 |
| Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure Immune-attractant, Durvalumab, Biopsy - Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Completed | UNICANCER | 61 | 2017-02-15 | 2020-09-30 |
| Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases Paclitaxel, Tamoxifen + Palbociclib, Aromatase Inhibitor + Palbociclib - Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor | Phase 2 | Active not recruiting | Thomas Hatschek | 181 | 2015-02-01 | 2021-08-03 |
| A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer Dietary supplementation with fish oil., Dietary supplementation with vegetable oil - Metastatic Breast Cancer, Progesterone Receptor Positive Tumor | Phase 3 | Terminated | University Hospital, Tours | 65 | 2012-02-01 | 2015-07-29 |
| Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer eribulin mesylate, capecitabine - Estrogen Receptor Positive Tumor, Breast Cancer | Phase 2 | Completed | Eisai Inc. | 77 | 2011-08-01 | 2023-06-22 |
| Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin - Metastatic Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Unknown | Samsung Medical Center | 147 | 2010-12-01 | 2017-05-01 |
Breast Neoplasms (15) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Adenosarcoma of the uterus (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Neoplasm, Residual (1) · Neuroendocrine Tumors (1) · Ovarian Neoplasms (1) · Perivascular Epithelioid Cell Neoplasms (1) · Rectal Neoplasms (1) · Sarcoma, Endometrial Stromal (1) · Urinary Bladder Neoplasms (1)
Neoplasms (17) · Breast Diseases (15) · Neoplasms by Site (15) · Skin Diseases (15) · Skin and Connective Tissue Diseases (15) · Neoplasms by Histologic Type (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2)
Paclitaxel (3) · Anastrozole (2) · Goserelin (2) · Letrozole (2) · Tamoxifen (2) · palbociclib (2) · ALX148 (1) · Aromatase Inhibitors (1) · Atorvastatin (1) · Biopsy (1) · Capecitabine (1) · Communication Devices for People with Disabilities (1) · Dietary Supplements (1) · Fish Oils (1) · Focus Groups (1)
Eisai Inc. (2) · Gangnam Severance Hospital (2) · QuantumLeap Healthcare Collaborative (2) · AC Camargo Cancer Center (1) · Aarhus University Hospital (1) · Dana-Farber Cancer Institute (1) · ETOP IBCSG Partners Foundation (1) · European Institute of Oncology (1) · First Affiliated Hospital of Zhejiang University (1) · North Eastern German Society of Gynaecological Oncology (1) · Samsung Medical Center (1) · Thomas Hatschek (1) · Thomas Jefferson University (1) · UNICANCER (1) · University Hospital, Tours (1)
United States (7) · France (4) · South Korea (3) · Italy (2) · Sweden (2) · Switzerland (2) · Belgium (1) · Brazil (1) · China (1) · Denmark (1) · Germany (1) · Spain (1) · United Kingdom (1)
Paula R Pohlmann, MD, MSc, PhD (2) · Anthony Elias, MD (1) · Etienne Brain, MD (1) · Fabrice Andre, Prof (1) · Giulio Tosti, MD (1) · Jonas Bergh, Professor (1) · Jonathan R Strosberg, MD (1) · Joon Jeong, Ph.D. (1) · Kuang-Yi Wen, MD (1) · Laura Biganzoli, MD (1) · Marion Kiechle, Prof. Dr. (1) · Peifen Fu, Doctor (1) · Philippe Bougnoux, MD, PhD (1) · Rachel SP Riechelmann, Phd (1) · Signe SB Borgquist, MD, PhD (1)
PMID 30223226, PMID 35642432, PMID 37529158, PMID 40830892, PMID 41612658, PMID 41951647, PMID 42142667
2016 (1), 2017 (1), 2018 (1), 2019 (1), R01CA222246 (1)